Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.
Malhotra S, Costa C, Eixarch H, Keller CW, Amman L, Martínez-Banaclocha H, Midaglia L, Sarró E, Machín-Díaz I, Villar LM, Triviño JC, Oliver-Martos B, Parladé LN, Calvo-Barreiro L, Matesanz F, Vandenbroeck K, Urcelay E, Martínez-Ginés ML, Tejeda-Velarde A, Fissolo N, Castilló J, Sanchez A, Robertson AAB, Clemente D, Prinz M, Pelegrin P, Lünemann JD, Espejo C, Montalban X, Comabella M. Malhotra S, et al. Brain. 2020 May 1;143(5):1414-1430. doi: 10.1093/brain/awaa084. Brain. 2020. PMID: 32282893 Free article.
TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis.
López-Gómez C, Fernández O, García-León JA, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Suardíaz M, García-Trujillo L, Guijarro-Castro C, Benito-León J, Prat I, Varadé J, Álvarez-Lafuente R, Urcelay E, Leyva L. López-Gómez C, et al. PLoS One. 2011;6(7):e21766. doi: 10.1371/journal.pone.0021766. Epub 2011 Jul 21. PLoS One. 2011. PMID: 21814551 Free PMC article.
ANKRD55 and DHCR7 are novel multiple sclerosis risk loci.
Alloza I, Otaegui D, de Lapuente AL, Antigüedad A, Varadé J, Núñez C, Arroyo R, Urcelay E, Fernandez O, Leyva L, Fedetz M, Izquierdo G, Lucas M, Oliver-Martos B, Alcina A, Saiz A, Blanco Y, Comabella M, Montalban X, Olascoaga J, Matesanz F, Vandenbroeck K. Alloza I, et al. Genes Immun. 2012 Apr;13(3):253-7. doi: 10.1038/gene.2011.81. Epub 2011 Dec 1. Genes Immun. 2012. PMID: 22130326
Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.
López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, Fernández Ó, Leyva L. López-Gómez C, et al. PLoS One. 2013 Apr 29;8(4):e62540. doi: 10.1371/journal.pone.0062540. Print 2013. PLoS One. 2013. PMID: 23658636 Free PMC article.
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.
López-Gómez C, Oliver-Martos B, Pinto-Medel MJ, Suardiaz M, Reyes-Garrido V, Urbaneja P, Fernández Ó, Leyva L. López-Gómez C, et al. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):130-7. doi: 10.1136/jnnp-2014-309932. Epub 2015 Mar 3. J Neurol Neurosurg Psychiatry. 2016. PMID: 25736057 Free PMC article.
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B. Órpez-Zafra T, et al. Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9. Mult Scler. 2017. PMID: 27613121
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium. Jensen PEH, et al. J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7. J Neuroimmunol. 2019. PMID: 30447419
The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis.
Melero-Jerez C, Suardíaz M, Lebrón-Galán R, Marín-Bañasco C, Oliver-Martos B, Machín-Díaz I, Fernández Ó, de Castro F, Clemente D. Melero-Jerez C, et al. Neurobiol Dis. 2019 Jul;127:13-31. doi: 10.1016/j.nbd.2019.02.014. Epub 2019 Feb 21. Neurobiol Dis. 2019. PMID: 30798007 Free article.
Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes.
Gil-Varea E, Spataro N, Villar LM, Tejeda-Velarde A, Midaglia L, Matesanz F, Malhotra S, Eixarch H, Patsopoulos N, Fernández Ó, Oliver-Martos B, Saiz A, Llufriu S, Ramió-Torrentà L, Quintana E, Izquierdo G, Alcina A, Bosch E, Navarro A, Montalban X, Comabella M. Gil-Varea E, et al. Hum Mutat. 2020 Jul;41(7):1308-1320. doi: 10.1002/humu.24016. Epub 2020 Apr 1. Hum Mutat. 2020. PMID: 32196808
33 results